Barclays
CSBR icon

Barclays’s Champions Oncology CSBR Stock Holding History

Barclays’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,342
Closed -$10K – 5282
2022
Q3 		$10K Buy
+1,342
New +$11.2K ﹤0.01% 4293
2021
Q4 		– Sell
-818
Closed -$8K – 4200
2021
Q3 		$8K Sell
818
-28
-3% -$285 ﹤0.01% 4544
2021
Q2 		$9K Sell
846
-4,812
-85% -$48.8K ﹤0.01% 4671
2021
Q1 		$64K Buy
5,658
+3,576
+172% +$41.5K ﹤0.01% 4148
2020
Q4 		$22K Sell
2,082
-1,176
-36% -$12.1K ﹤0.01% 4656
2020
Q3 		$30K Sell
3,258
-723
-18% -$6.44K ﹤0.01% 4799
2020
Q2 		$38K Buy
+3,981
New +$33.9K ﹤0.01% 5032
2019
Q2 		– Sell
-47
Closed – – 6975
2019
Q1 		$0 Buy
+47
New +$468 ﹤0.01% 7049

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
MAG
Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays's CSBR Position: Q4 2022 in Review

Barclays sold out of Champions Oncology (CSBR) in Q4 2022, closing a stake of 1,342 shares — an estimated $10K sold.

Barclays first reported a position in CSBR in Q1 2019 and held it in 8 quarters. The position peaked at $64K in Q1 2021. 29 funds tracked by Wall St. Rank hold CSBR as of Q4 2022.

  • Barclays reported no remaining Champions Oncology position as of Q4 2022 after selling out during the quarter.
  • Barclays sold 1,342 Champions Oncology shares in Q4 2022, an estimated $10K.
  • Barclays first reported a position in Champions Oncology in Q1 2019 and held it in 8 quarters.
  • Barclays's Champions Oncology position peaked at $64K in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Champions Oncology as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.